23 October 2020 in Science Advances
Integrative proteomic analysis identifies CSF biomarker panels linked to brain-based pathophysiologies in Alzheimer’s disease.
6 September 2021 in Health Research Policy and Systems
Background: In the era of evidence-based policy-making (EBPM), scientific outputs and public policy should engage with each other in a more interactive and coherent way. Notably, this is becoming increasingly critical in preparing for public health emergencies. Methods: To explore the coevolution dynamics between science and policy (SAP), this study explored the changes in, and development of, COVID-19 research in the early period of the COVID-19 outbreak in China, from 30 December 2019 to 26 June 2020. In this study, VOSviewer was adopted to calculate the link strength of items extracted from scientific publications, and machine learning clustering analysis of scientific publications was carried out to explore dynamic trends in scientific research. Trends in relevant policies that corresponded to changing trends in scientific research were then traced. Results: The study observes a salient change in research content as follows: an earlier focus on “children and pregnant patients”, “common symptoms”, “nucleic acid test”, and “non-Chinese medicine” was gradually replaced with a focus on “aged patients”, “pregnant patients”, “severe symptoms and asymptomatic infection”, “antibody assay”, and “Chinese medicine”. “Mental health” is persistent throughout China’s COVID-19 research. Further, our research reveals a correlation between the evolution of COVID-19 policies and the dynamic development of COVID-19 research. The average issuance time of relevant COVID-19 policies in China is 8.36 days after the launching of related research. Conclusions: In the early stage of the outbreak in China, the formulation of research-driven-COVID-19 policies and related scientific research followed a similar dynamic trend, which is clearly a manifestation of a coevolution model (CEM). The results of this study apply more broadly to the formulation of policies during public health emergencies, and provide the foundation for future EBPM research.
16 October 2019 in bioRxiv
Alzheimer’s disease (AD) features a complex web of pathological processes beyond amyloid accumulation and tau-mediated neuronal death. To meaningfully advance AD therapeutics, there is an urgent need for novel biomarkers that comprehensively reflect these disease mechanisms. Here we applied an integrative proteomics approach to identify cerebrospinal fluid (CSF) biomarkers linked to a diverse set of pathophysiological processes in the diseased brain. Using multiplex proteomics, we identified >3,500 proteins across 40 CSF samples from control and AD patients and >12,000 proteins across 48 postmortem brain tissues from control, asymptomatic AD (AsymAD), AD, and other neurodegenerative cases. Co-expression network analysis of the brain tissues resolved 44 protein modules, nearly half of which significantly correlated with AD neuropathology. Fifteen modules robustly overlapped with proteins quantified in the CSF, including 271 CSF markers highly altered in AD. These 15 overlapping modules were collapsed into five panels of brain-linked fluid markers representing a variety of cortical functions. Neuron-enriched synaptic and metabolic panels demonstrated decreased levels in the AD brain but increased levels in diseased CSF. Conversely, glial-enriched myelination and immunity panels were highly increased in both the brain and CSF. Using high-throughput proteomic analysis, proteins from these panels were validated in an independent CSF cohort of control, AsymAD, and AD samples. Remarkably, several validated markers were significantly altered in AsymAD CSF and appeared to stratify subpopulations within this cohort. Overall, these brain-linked CSF biomarker panels represent a promising step toward a physiologically comprehensive tool that could meaningfully enhance the prognostic and therapeutic management of AD.
2 September 2020 in Research Square
The dynamics of research are a prism that reflects interactions between science, the societal environment, and government policies. Against the backdrop of the ongoing global COVID-19 pandemic, this study explored the changes in, and development of, COVID-19 research in the period from December 30, 2019 to April 27, 2020. The study observes a salient change in research content: an earlier focus on “all patients”, “common symptoms”, and “nucleic acid test” was gradually replaced by a focus on “children”, “pregnant patients”, “severe symptoms”, and a combination of “nucleic acid test” and “antibody assay”. Some topics such as “vaccine R&D”, “knowledge, attitude, and practice” (KAP), and “mental health” were persistent throughout the recent history of China’s COVID-19 research. This study also reveals a correlation between the evolution of COVID-19 policies and the dynamic development of COVID-19 research. In the early stage of the outbreak in China, the formulation of COVID-19 policies followed a rapidly-progressing co-evolutionary model (CEM). The results of this study apply more broadly to the formulation of policies in public health emergencies, especially in the early stages.